Abstract
Asthma is one of the most common chronic diseases of childhood with significant morbidity. Management of asthma has evolved from inhaled corticosteroids to personalized therapy in recent years. This article summarizes the recent advances in the management of asthma. The severity of asthma is assessed retrospectively by the level of treatment required to control asthma symptoms.
Recently, there has been an emphasis on not to use short-acting beta-2 agonist (SABA) alone, even for intermittent or mild asthma. Single maintenance and reliever therapy (MART) is increasingly being recommended. Asthma therapy should be personalized based on phenotype (clinical presentations) and endotypes (distinct mechanistic pathways) of asthma and by a continuous cycle of assessment of asthma control and risk assessment, treatment, and reviewing the response in children on treatment. Various add-on therapy like tiotropium and biological monoclonal antibodies have been approved for use in a subset of children with severe asthma. Before considering biologicals, it is vital to have a proper diagnosis, good compliance and inhaler technique, and treatment of comorbidities.
Similar content being viewed by others
References
Gaillard EA, Kuehni CE, Turner S, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years. Eur Respir J. 2021;58:2004173.
2021 GINA Main Report. Global Initiative for Asthma - GINA. 2021. Available at: https://ginasthma.org/gina–reports/. Accessed on 7 May 2021.
Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:650–7.
Sumino K, Bacharier LB, Taylor J, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract. 2020;8:176–85.
Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), Cloutier MM, Baptist AP, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146:1217–70
Sunther M, Marchon K, Gupta A. Tiotropium in the management of paediatric and adolescent asthma: systematic review. Paediatr Respir Rev. 2021;38:58–62.
Gupta RS, Fierstein JL, Boon KL, et al. Sensor-based electronic monitoring for asthma: a randomized controlled trial. Pediatrics. 2021;147:e20201330.
Shields MD, ALQahtani F, Rivey MP, McElnay JC. Mobile direct observation of therapy (MDOT) – A rapid systematic review and pilot study in children with asthma. PloS One. 2018;13:e0190031.
Kuruvilla ME, Lee FE-H, Lee GB. Understanding asthma Ppenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56:219–33.
Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017;8:CD005603.
Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev. 2016;11:CD011439.
Irving S, Fleming L, Ahmad F, et al. Lung clearance index and steroid response in pediatric severe asthma. Pediatr Pulmonol. 2020;55:890–8.
Russo D, Di Filippo P, Attanasi M, Lizzi M, Di Pillo S, Chiarelli F. Biologic therapy and severe asthma in children. Biomedicines. 2021;9:760.
Cevhertas L, Ogulur I, Maurer DJ, et al. Advances and recent developments in asthma in 2020. Allergy. 2020;75:3124–46.
Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476–85.
Gupta A, Pouliquen I, Austin D, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019;54:1957–67.
Gupta A, Ikeda M, Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144:1336–42.
Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate–to–Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486–96.
Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab efficacy and safety in children with uncontrolled, moderate-to-severe asthma: the phase 3 VOYAGE study. Am J Respir Crit Care Med. 2021;203:A1204.
Abrams EM, Becker AB, Szefler SJ. Current state and future of biologic therapies in the treatment of asthma in children. Pediatr Allergy Immunol Pulmonol. 2018;31:119–31.
Jackson DJ, Bacharier LB, Mauger DT, et al. Quintupling inhaled Ggucocorticoids to prevent childhood asthma exacerbations. N Engl J Med. 2018;378:891–901.
Thomas M, Bruton A. Breathing exercises for asthma. Breathe. 2014;10:312–22.
Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020;9:CD011293.
Gupta A, Sjoukes A, Richards D, et al. Relationship serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med. 2011;184:1342–9.
Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017;5:881–90.
Forno E, Bacharier LB, Phipatanakul W, et al. Effect of vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA. 2020;324:752–60.
Jat KR, Goel N, Gupta N, et al. Efficacy of vitamin D supplementation in asthmatic children with vitamin D deficiency: A randomized controlled trial (ESDAC trial). Pediatr Allergy Immunol. 2021;32:479–88.
Boyle RJ, Pedroletti C, Wickman M, et al; 4A Study Group. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax. 2012;67:215–21.
Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145:757–65.
Author information
Authors and Affiliations
Contributions
KRJ: Literature search, manuscript writing, and final approval of manuscript; AG: Critical intellectual input, review of manuscript, and final approval of manuscript. KRJ will act as the guarantor for this paper.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jat, K.R., Gupta, A. Recent Advances in Long-Term Management of Asthma. Indian J Pediatr 89, 378–386 (2022). https://doi.org/10.1007/s12098-021-04060-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-021-04060-5